ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Holdings Lessened by Alliancebernstein L.P.

Alliancebernstein L.P. cut its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 12.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 53,870 shares of the company’s stock after selling 8,000 shares during the period. Alliancebernstein L.P.’s holdings in ORIC Pharmaceuticals were worth $435,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in ORIC. Barclays PLC grew its holdings in shares of ORIC Pharmaceuticals by 111.2% during the 3rd quarter. Barclays PLC now owns 107,261 shares of the company’s stock valued at $1,100,000 after acquiring an additional 56,474 shares in the last quarter. Geode Capital Management LLC increased its position in ORIC Pharmaceuticals by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,273,513 shares of the company’s stock worth $13,056,000 after purchasing an additional 50,821 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of ORIC Pharmaceuticals by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 950,459 shares of the company’s stock worth $9,067,000 after purchasing an additional 196,804 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of ORIC Pharmaceuticals by 3.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 35,251 shares of the company’s stock valued at $361,000 after buying an additional 1,279 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its holdings in ORIC Pharmaceuticals by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 162,909 shares of the company’s stock worth $1,315,000 after buying an additional 24,947 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

Analyst Upgrades and Downgrades

ORIC has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their target price on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, January 14th. Guggenheim reissued a “buy” rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a research report on Friday, February 21st. Finally, Wedbush reissued an “outperform” rating and issued a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Thursday, March 20th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, ORIC Pharmaceuticals presently has an average rating of “Buy” and an average target price of $18.86.

ORIC Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ ORIC opened at $4.77 on Monday. ORIC Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.67. The company has a market cap of $338.80 million, a P/E ratio of -2.62 and a beta of 1.38. The business’s 50 day moving average is $6.72 and its two-hundred day moving average is $8.48.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Tuesday, February 18th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.01. Sell-side analysts expect that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.